{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:29:33Z","timestamp":1754162973154,"version":"3.41.2"},"reference-count":19,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2020,11,18]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Hepatitis C virus (HCV) related liver cirrhosis is considered a major health problem; sofosbuvir (SOF)\/ledipasvir (LDV) and SOF\/daclatsvir (DACLA) are very promising direct antiviral agents (DAAS) especially in treating HCV genotype 4 which is the main genotype in Egypt. Uric acid elevation was reported in many systemic diseases and might be elevated during direct antiviral therapy. The aim is to evaluate efficacy and safety of SOF\/LDV and SOF\/DACLA plus ribavirin in treating HCV related child A liver cirrhosis and assess hyperuricaemia as a potential adverse effect to this regimen.<\/jats:p>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective observatinal study included 128 HCV naive child A cirrhotic patients divided into two groups (77 patients were treated with SOF 400\u2009mg, DACLA 60\u2009mg and ribavirin 600\u2009mg and 51 patients were treated with SOF 400\u2009mg, LDV 90\u2009mg and ribavirin 600\u2009mg) for 12 weeks, during the treatment complete blood count, creatinine, bilirubin, alanine transaminase, aspartate transaminase and serum uric acid were monitored, HCV RNA quantitative PCR at 12 weeks after the end of treatment was done.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Response to treatment in SOF\/LDV (sof\/led) group is about (98%), response to treatment in SOF\/DACLA (sof\/dacla) group is about (96%). Hyperuricaemia was noticed in 17.6% of patients received sof\/led and in 15.5% of those received sof\/dacla.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SOF+LDV\u2009and SOF+DACLA\u2009plus ribavirin regimens are highly effective in treating chronic HCV patients with compensated liver cirrhosis. Hyperuricaemia is considered a potential adverse effect to DAAS containing ribavirin and may lead to serious side effects such as renal impairment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2020-000533","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T09:45:32Z","timestamp":1607766332000},"page":"e000533","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?"],"prefix":"10.1136","volume":"7","author":[{"given":"Amr","family":"Elsayed","sequence":"first","affiliation":[{"name":"Gasteroentrology and Tropical Diseases, Minia University Faculty of Medicine, El Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab","family":"M Abdelraheem","sequence":"additional","affiliation":[{"name":"Gasteroentrology and Tropical Diseases, Minia University Faculty of Medicine, El Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Minia University Faculty of Medicine, El Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Cairo University Kasr Alainy Faculty of Medicine, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-0948","authenticated-orcid":false,"given":"Alshymaa","family":"Hassnine","sequence":"additional","affiliation":[{"name":"Gasteroentrology and Tropical Diseases, Minia University Faculty of Medicine, El Minia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"2025073013373864000_7.1.e000533.1","first-page":"154","article-title":"Direct-Acting antiviral medications for chronic hepatitis C virus infection","volume":"7","author":"Jazwinski","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"2025073013373864000_7.1.e000533.2","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","article-title":"Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations","volume":"24","author":"Omran","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025073013373864000_7.1.e000533.3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2888"},{"key":"2025073013373864000_7.1.e000533.4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jgh.12313","article-title":"Chronic hepatitis C infection is associated with insulin resistance and lipid profiles","volume":"30","author":"Dai","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2025073013373864000_7.1.e000533.5","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00039.2004"},{"key":"2025073013373864000_7.1.e000533.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.08.023"},{"key":"2025073013373864000_7.1.e000533.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9616234","article-title":"Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village","volume":"2018","author":"Ahmed","year":"2018","journal-title":"Int J Hepatol"},{"key":"2025073013373864000_7.1.e000533.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"2025073013373864000_7.1.e000533.9","first-page":"155A","article-title":"A simplified equation to predict glomerular filtration from serum creatinine (Abstract)","volume":"11","author":"Levey","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2025073013373864000_7.1.e000533.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"2025073013373864000_7.1.e000533.11","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"key":"2025073013373864000_7.1.e000533.12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: the role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res"},{"key":"2025073013373864000_7.1.e000533.13","doi-asserted-by":"crossref","unstructured":"Wyles D , Ruane PJ , Sulkowski M , et al . (K Sherman presenting). Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: the ALLY-2 study. Digestive Disease Week 2015:Abstract 901d:6\u201319.","DOI":"10.1016\/S0016-5085(15)34078-6"},{"key":"2025073013373864000_7.1.e000533.14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/apt.14482","article-title":"Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4","volume":"47","author":"El-Khayat","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013373864000_7.1.e000533.15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/sjamf.sjamf_32_18","article-title":"Impact of direct-acting antiviral therapy in Egyptian patients with chronic Hep C and liver cirrhosis","volume":"2","author":"Elnadry","year":"2018","journal-title":"The Scientific Journal of Al-Azhar Medical Faculty,Girls"},{"key":"2025073013373864000_7.1.e000533.16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/liv.12724","article-title":"Optimal therapy in genotype 4 chronic hepatitis C: finally cured?","volume":"35(Suppl 1)","author":"Abdel-Razek","year":"2015","journal-title":"Liver Int"},{"key":"2025073013373864000_7.1.e000533.17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cld.663","article-title":"HCV treatment in patients with decompensated liver disease","volume":"10","author":"Verna","year":"2017","journal-title":"Clin Liver Dis"},{"key":"2025073013373864000_7.1.e000533.18","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1111\/hepr.12971","article-title":"Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin","volume":"48","author":"Sato","year":"2018","journal-title":"Hepatol Res"},{"key":"2025073013373864000_7.1.e000533.19","unstructured":"Interview form of SOVALDI tablets 400 mg. (In Japanese). 6th edn, 2017: 71\u20132."}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2020-000533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:37:43Z","timestamp":1753907863000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2020-000533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,12]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bmjgast-2020-000533"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2020-000533","relation":{},"ISSN":["2054-4774"],"issn-type":[{"type":"electronic","value":"2054-4774"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}